synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-14 and is reviewed periodically as new material appears.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
== Properties == Ethyl cyanohydroxyiminoacetate is a white solid which is soluble in many solvents common in the synthesis of peptides, such as dichloromethane or dimethylformamide (DMF). In crystalline form, the compound is present as an oxime, whereas it exists as a salt or in a strongly basic solution predominantly as a tautomeric nitroso isomer in anionic form.
A study by Hutchinson and colleagues in 2011 corroborated the previous estimation methods in general, but their estimation of peak growth rates is significantly higher; it found that the "maximum growth rates for T. rex during the exponential stage are 1790 kg/year". Although these results were much higher than previous estimations, the authors noted that these results significantly lowered the great difference between its actual growth rate and the one which would be expected of an animal of its size. The sudden change in growth rate at the end of the growth spurt may indicate physical maturity, a hypothesis which is supported by the discovery of medullary tissue in the femur of a 16 to 20-year-old T. rex from Montana (MOR 1125, also known as B-rex). Medullary tissue is found only in female birds during ovulation, indicating that B-rex was of reproductive age. Further study indicates an age of 18 for this specimen. In 2016, it was finally confirmed by Mary Higby Schweitzer and Lindsay Zanno and colleagues that the soft tissue within the femur of MOR 1125 was medullary tissue. This also confirmed the identity of the specimen as a female. The discovery of medullary bone tissue within Tyrannosaurus may prove valuable in determining the sex of other dinosaur species in future examinations, as the chemical makeup of medullary tissue is unmistakable. Other tyrannosaurids exhibit extremely similar growth curves, although with lower growth rates corresponding to their lower adult sizes.
=== Synthesis === The chemical synthesis of ibogaine has been described. One recent total synthesis of ibogaine and related drugs starts with 2-iodo-4-methoxyaniline which is reacted with triethyl((4-(triethylsilyl)but-3-yn-1-yl)oxy)silane using palladium acetate in DMF to form 2-(triethylsilyl)-3-(2-((triethylsilyl)oxy)ethyl)-1H-indole. This is converted using N-iodosuccinamide and then fluoride to form 2-(2-iodo-1H-indol-3-yl)ethanol. This is treated with iodine, triphenyl phosphine, and imidazole to form 2-iodo-3-(2-iodoethyl)-1H-indole. Then, using 7-ethyl-2-azabicyclo[2.2.2]oct-5-ene and cesium carbonate in acetonitrile, the ibogaine precursor 7-ethyl-2-(2-(2-iodo-1H-indol-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene is obtained. Using palladium acetate in DMF, the ibogaine is obtained. If the exo ethyl group on the 2-azabicyclo[2.2.2]octane system in ibogaine is replaced with an endo ethyl, then epiibogaine is formed. Crystalline ibogaine hydrochloride is typically produced by semisynthesis from voacangine in commercial laboratories. It can be prepared from voacangine through one-step demethoxycarbonylation process too. In 2025, researchers at the University of California, Davis Institute for Psychedelics and Neurotherapeutics reported the total synthesis of ibogaine, ibogaine analogues, and related compounds from pyridine.
6 July – BBC News reports that Reform UK would be highly unlikely to introduce an insurance based healthcare system in Wales should it win the 2026 Senedd election, largely because of the timescale and potential legal implications of doing so. 7 July – David Jones, a former Conservative Secretary of State for Wales who stepped down from Parliament at the 2024 election, announces he is defecting to Reform UK. Amazon removes a number of AI-generated unofficial biographies of Scotland's first ministers from sale after BBC News alerts them to a significant number of inaccuracies contained within the books. 8 July – French President Emmanuel Macron begins a three-day state visit to the UK, becoming the first French President to visit the UK since 2008, and the first European leader to do so since Brexit. Former prime minister Rishi Sunak joins Goldman Sachs as a senior advisor. James McMurdock says he will not return to Reform UK after asking to have the party whip withdrawn. Sir Robert Chote resigns as chairman of the UK Statistics Authority, the body that oversees the Office for National Statistics. MPs vote 415–98 to approve the Football Governance Bill that will establish a regulatory body for the top five tiers of English football. 9 July – Secretary of State for Wales Jo Stevens says public services in Wales will not face cuts despite a shortfall in covering a rise in employers' National Insurance contributions. Her comments follow a warning from Welsh Government Finance Secretary Mark Drakeford, who warned Wales was facing a £36m financial black hole.
Sources: en.wikipedia.org
The growth solution requires a low concentration of a metal precursor, ligands that will readily exchange with preexisting seed ligands, and a weak or very low concentration of reducing agent. The reducing agent must not be strong enough to reduce metal precursor in the growth solution in the absence of seeds. Otherwise, the growth solution will form new nucleation sites instead of growing on preexisting ones (seeds). Growth is the result of the competition between surface energy (which increases unfavorably with growth) and bulk energy (which decreases favorably with growth). The balance between the energetics of growth and dissolution is the reason for uniform growth only on preexisting seeds (and no new nucleation). Growth occurs by the addition of metal atoms from the growth solution to the seeds, and ligand exchange between the growth ligands (which have a higher bonding affinity) and the seed ligands. Range and direction of growth can be controlled by nanoseed, concentration of metal precursor, ligand, and reaction conditions (heat, pressure, etc.). Controlling stoichiometric conditions of growth solution controls ultimate size of particle. For example, a low concentration of metal seeds to metal precursor in the growth solution will produce larger particles. Capping agent has been shown to control direction of growth and thereby shape. Ligands can have varying affinities for binding across a particle. Differential binding within a particle can result in dissimilar growth across particle.
=== Nanomaterials === Nanomaterials include carbon-based materials, metal oxides, metals, and quantum dots. Nanomaterials can enter the environment during their manufacturing, consumer use, or disposal. Due to their small size, nanomaterials behave differently than larger particles. They have a high surface area to volume ratio, which can lead to increased reactivity and the potential to transport throughout the environment. Nanomaterials are challenging to detect and monitor due to their size and the absence of standardized methods for measuring their presence and concentration in various media.
The odontoblast-like cell is a mineralized structure formed by a new population of pulp-derived cells that can be expressed as Toll-like receptors. They are responsible for the upregulation of innate immunity effectors, including antimicrobial agents and chemokines. One important antimicrobial agent produced by odontoblasts is beta-defensins (BDs). BDs kill microorganisms by forming micropores that destroy membrane integrity and cause leakage of the cell content. Another is nitric oxide (NO), a highly diffusible free radical that stimulates chemokine production to attract immune cells to the affected areas and neutralize bacterial by-products in pulp cells in vitro.
This occurred due to DOM being publicly distributed for free in the form of high-dose tablets by LSD distributor Owsley Stanley, who had personally learned of DOM from Shulgin. It is unclear why Shulgin provided information about DOM to Stanley, since doing so had the potential to risk Shulgin's professional career and the DOET clinical studies. One possibility is that Dow Chemical Company was not further looking into DOM and Shulgin thought that it was a promising drug that would otherwise be forgotten. In any case, street use of DOM was short-lived because the tablets caused a public health crisis due to them often producing very long durations (up to 3–4 days), intense experiences, worrying physical side effects, and hospitalizations. DOM was first reported on in the media and scientific literature in 1967 as a result of the crisis. DOM became illegal in the United States in 1968. Dow Chemical Company terminated its clinical research program on DOET due to the DOM public health crisis. DOET was subsequently first described in the literature by Snyder and colleagues in 1968. Snyder continued to be interested in DOET as a potential medicine, but it was never further developed. Snyder also described 2,5-dimethoxyamphetamine (2,5-DMA), which had been synthesized and tested by Shulgin, in the literature in 1968. DOM and DOET were further described in the scientific literature by Shulgin in 1969. In addition, Shulgin discussed DOM, DOET, TMA-2, and 2,5-DMA in a book chapter on hallucinogens published in 1970.
These events caused widespread devastation, and even depopulated the north, resulting in the complete social and political breakdown and collapse of central authority in the Central Plains, triggering massive, sustained waves of Han Chinese migration into South China, leading to the formation of distinct Han lineages, who also likely assimilated the by-now partially sinicized Bai Yue in their midst. Modern Han Chinese subgroups, such as the Cantonese, the Hakka, the Henghua, the Hainanese, the Hoklo peoples, the Gan, the Xiang, the Wu-speaking peoples, all claim Han Chinese ancestry pointing to official histories and their own genealogical records to support such claims. Linguists hypothesize that proto- Wu and Min varieties of Chinese may have originated from the time of Jin, while the proto- Yue and Hakka varieties perhaps from the Tang and Song, about half-a-millennium later. The presence of Tai-Kradai substrates in these dialects may have been due to the assimilation of the remaining groups of Bai Yue, integrating these lands into the Sinosphere proper.
Sources: en.wikipedia.org
In 1995, the Insurance Institute for Highway Safety (IIHS) began frontal offset crash tests. Also in the same year, Volvo introduced the world's first car with side airbags: the 850. In 1996, the European New Car Assessment Programme (Euro NCAP) was established to test new vehicles' safety performance and publish the results for vehicle shoppers' information. The NHTSA crash tests are presently operated and published as the U.S. branch of the international NCAP programme.
Guillaume made several guest appearances on sitcoms, including Good Times, The Jeffersons, Sanford and Son, Saved by the Bell: The College Years and in the 1990s sitcoms The Fresh Prince of Bel-Air and A Different World. Guillaume also played Dr. Franklin in season 6, episode 6 ("Chain Letter") of the series All in the Family, in which he coyly referenced Marcus Welby, M.D., a TV series in which he had guest-starred in 1970. His series-regular debut was on the ABC series Soap, playing Benson, a butler, from 1977 to 1979. Guillaume continued the role in a spin-off series, Benson, which ran for 158 episodes from 1979 until 1986. In 1985, Guillaume appeared in the television mini-series North and South as abolitionist leader Frederick Douglass, who escaped from slavery and became a leader of the anti-slavery movement prior to the American Civil War. He also appeared as marriage counselor Edward Sawyer on The Robert Guillaume Show (1989), Detective Bob Ballard on Pacific Station (1991–1992), and television executive Isaac Jaffe on Aaron Sorkin's short-lived but critically acclaimed Sports Night (1998–2000). Guillaume suffered a mild stroke on January 14, 1999, while filming an episode of the latter series. He recovered and his character was later also depicted as having had a stroke. He also made a guest appearance on 8 Simple Rules for Dating My Teenage Daughter.
Technology companies have built electricity and artificial intelligence infrastructure to facilitate the AI boom of the 2020s. A 2025 report from the consulting firm McKinsey & Company estimated that by 2030, $2.7 trillion would be invested into AI infrastructure and data centres in the US, surpassing World War II's Manhattan Project every month. In January 2024, the International Energy Agency (IEA) released Electricity 2024, Analysis and Forecast to 2026. This is the first IEA report to make projections for data centres and power consumption by AI and cryptocurrency. The report states that power demand for these uses might double by 2026, with the additional power consumption equaling that of Japan. Power consumption by AI is responsible for an increase in fossil fuel use, and has delayed closings of obsolete, carbon-emitting coal energy facilities. A ChatGPT search involves 10 times as much electrical energy as a Google search. A 2024 Goldman Sachs research paper, AI Data Centers and the Coming US Power Demand Surge, found "US power demand (is) likely to experience growth not seen in a generation...." and forecasts that, by 2030, US data centres will consume 8% of US power, as opposed to 3% in 2022, presaging growth for the electrical power generation industry by a variety of means. Data centres' need for more and more electrical power is such that they might max out the electrical grid. The Big Tech companies counter that AI can be used to maximise the utilisation of the grid by all.
(See also: Al Gore and information technology) Kodak did not refuse to invest in digital cameras, but was rather a pioneer in the field, and at one point was the market leader in digital camera sales in the United States.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.